Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Autor:	Bamias, A. De Santis, M. Arranz, J. A. Grande, E. and Galsky, M. D. Kikuchi, E. Park, S. H. De Giorgi, U. and Garcia del Muro, X. Mencinger, M. Alekseev, B. Puente, J. and Izumi, K. Gumus, M. Mellado Gonzalez, B. Li, J-R. and Quach, C. Ding, B. Bernhard, S. Davis, I. D.
Jazyk:	angličtina
Rok vydání:	2020
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______2127::3c9b8ae358c738368178abba65412d48 https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3192210 Zobrazit plný text záznamu